The Precision GI™ Endoscopic Ultrasound Biopsy Device reportedly provides a more efficient and less traumatic method of obtaining biopsy tissue for suspected gastrointestinal cancers.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Precision GITM Endoscopic Ultrasound (EUS) Biopsy Device, which may facilitate improved quality and quantity of biopsy tissue.
For pancreatic cancer and other gastrointestinal (GI) cancers, the Precision GI ultrasound device enables clinicians to obtain “significantly superior quality and quantity of diagnostically relevant biopsy tissue,” according to Limaca Medical, the manufacturer of the Precision GI Endoscopic Ultrasound Biopsy Device.
Iyad Khamaysi, M.D., said the automation with the Precision GI ultrasound tool provides a notable contrast to other endoscopic biopsy modalities.
“While all existing endoscopic ultrasound fine needle biopsy (EUS-FNB) devices require manual hand operation, Precision GI features a unique motorized, automated rotational cutting needle for successful, safe, and high-quality tissue acquisition,” noted Iyad Khamaysi, M.D., the director of the Invasive Endoscopy Unit at the Rambam Health Care Campus in Haifa, Israel.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.